Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2020–2024

TrainCKDis · Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2020-01-01 → 2024-06-30
EU contribution
€4,017,848
Participants
10
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

Multidisciplinary Training in Chronic Kidney Disease: from genetic modifiers to drug discovery

The goal of TrainCKDis is to provide high-level training in chronic kidney disease (CKD) - a global public health burden - to a new generation of highly achieving early stage researchers. TrainCKDis will develop scientific skills necessary for thriving careers in an expanding area that underpins innovative technological development across a range of diverse disciplines including nephrology, epidemiology, genetics, cell biology, and drug discovery at the interface of basic molecular, genetic and clinical research. We will achieve this by a unique combination of “hands-on” research training, non-academic placements, courses and workshops on scientific and transferable skills, facilitated by the consortium academic/non-academic composition. Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, lasting longer than three months. CKD is an increasing global health problem; its prevalence and associated burden are rising worldwide1. CKD affects 10-15% of the population, with unexplained regional variation across Europe. About 70 million Europeans have suboptimal kidney function and are at increased risk of kidney failure, a fatal condition without renal replacement therapies (RRT) such as dialysis or transplantation. The key research challenges are: 1) Identify genetic and epigenetic modifiers that predispose patients to CKD progression; 2) Uncover signalling pathways and innovative biomarkers essential for monitoring disease evolution and clinical trials outcomes; 3) Discover novel therapeutic targets to expand the limited CKD treatments.

Data: CORDIS, © European Union

Project objective

Chronic kidney disease (CKD) is recognized as an increasing global health problem. It currently affects 10-15% of the worldwide population, is associated with impaired quality of life and reduced life expectancy, and represents a significant burden for health care budgets.CKD is characterized by the progressive decline of renal function. Little is known about the mechanisms underlying this progression and the genetic factors that predispose patients to different rate of progression. Even worse, there is no reliable biomarkers capable to identify patients at risk of fast progression and treatments able to halt CKD progression.Understanding the physiopathology of CKD is therefore a prerequisite for the development of efficient preventive strategies and diagnostic tools.With this goal in mind, TrainCKDis will provide an innovative, multidisciplinary, and intersectoral training programme, able to prepare top-level young scientists to develop creative solutions for CKD. The proposed 15 research projects will address key challenges: i) the identification of genetic and epigenetic modifiers that predispose patients to CKD progression, ii) the identification of pathways and biomarkers for monitoring CKD progression and iii) the identification of novel therapeutic targets to improve the limited treatments for CKD.TrainCKDis gathers top European laboratories, companies, hospitals, and associations involved in the treatment of CKD.Early Stage Researchers (ESRs) will thus benefit from an outstanding interdisciplinary platform integrating nephrology, epidemiology, genetics, cell biology, high-throughput screening, system biology, and metabolomics experts, as well as experimental animal models and unique human biobanks. Moreover, ESRs will be trained in disseminating results through modern channels of communication. Finally, TrainCKDis will provide ESRs with intersectoral and transferable training for efficient career development in both the academic and private sectors.

Original text from CORDIS.

Participants

  • UNIVERSITE PARIS CITE · ParisCoordinatorFrance
  • ACADEMISCH ZIEKENHUIS LEIDEN · LeidenNetherlands
  • ACCADEMIA EUROPEA DI BOLZANO · BolzanoItaly
  • ASTRAZENECA AB · SodertaeljeSweden
  • CHARITE - UNIVERSITAETSMEDIZIN BERLIN · BerlinGermany
  • GenomeScan B.V. · LeidenNetherlands
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE · ParisFrance
  • ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI · MILANOItaly
  • UNIVERSITAETSKLINIKUM FREIBURG · FreiburgGermany
  • UNIVERSITAT ZURICH · ZurichSwitzerland

Links

Data: CORDIS, © European Union